FOSTER JAMES C

CRL CEO Foster buys 6,075 shares at $165.01; stock down 33.5% from 52-week high, now $163.02

FOSTER JAMES C, the Chairman, President and CEO, purchased 6,075 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. at $165.01 on 2025-02-20, increasing his holdings from 177,564 to 183,639 shares. The purchase occurs as the stock trades at $163.02, down 33.5% from its 52-week high of $245.29 and down 16.7% over the past 90 days. Across his open-market trade history, Foster's prior sell at this ticker (2024-08-01) exhibited a 90-day return of -27.4%, which was well-timed, though his lone measurable buy outcome at CRL is not yet available. The company's fundamentals show annual revenue growth of -1.9%, with a notably elevated P/E of 815.10 relative to net income of $69,657,000.00, warranting scrutiny of earnings quality and sustainability.

CEO James Foster sold 25,000 CRL shares at $250.00 for $6.2M on 2024-08-01, reducing stake to 188.3K shares (-11.7%).

James C. Foster, Chairman, President and CEO of Charles River Laboratories, sold 25,000 shares at $250.00 on 2024-08-01, raising $6,250,000.00, which represents an 11.7% reduction in his post-transaction holdings to 188,251 shares. The sale occurred at a price point that was $23.60 above the current market price of $226.40, and the stock has since declined 4.2% over the 90-day period following the transaction, suggesting the sale preceded a broader pullback from the transaction price. While Foster's cross-ticker track record shows strong timing (100% win rate with +26.8% average 90-day returns on prior buys), his one prior buy at CRL on 2023-11-14 returned +26.8% over 90 days; this current sell-side transaction and the subsequent stock performance offer a contrasting data point for same-ticker assessment. The company's fundamentals remain solid with $1,011,560,000.00 in latest-quarter revenue and $72,960,000.00 in net income, with a P/E of 26.23, though the stock is currently -17.2% from its 52-week high of $273.43.